Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
extension source : Www.biospace.com save search
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Published: 2024-04-08 (Crawled : 14:00) - biospace.com/
JAGX | News | $0.1704 1.43% 1.41% 34M
|
Health Technology
|
| O: 7.14%
H: 1.11%
C: -8.89%
health granted extension
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
NRIX 6 d | $13.73 -2.83% -2.91% 520K
|
Health Technology
|
| O: -1.59%
H: 6.37%
C: 4.57%
sciences collaboration extension therapeutics
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
Published: 2024-03-25 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.29%
H: 1.27%
C: 0.33%
cardiovascular cardiology
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
Published: 2024-03-21 (Crawled : 12:30) - biospace.com/
CRL | News | $239.43 -0.29% -5.0% 710K
|
Commercial Services
|
| O: 0.68%
H: 1.71%
C: 1.27%
extension therapy
Aptar Pharma Continues Global Expansion with North America Capacity Extension at Congers, New York Site
Published: 2024-03-14 (Crawled : 13:30) - biospace.com/
ATR | $140.01 0.19% 0.0% 430K
|
Process Industries
|
| O: 0.14%
H: 0.18%
C: -0.3%
america pharma capacity expansion global extension
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
Published: 2024-02-14 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
management series extension therapeutics
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
THRX | $4.06 0.49% 0
|
|
| O: 1.87%
H: 0.49%
C: -0.49%
pharmaceuticals extension
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Published: 2024-01-09 (Crawled : 15:30) - biospace.com/
SNOA | $0.155 -2.52% -2.58% 120K
|
Health Technology
|
| O: 2.18%
H: 23.66%
C: 0.55%
NBY | $0.0773 0.39% 0.0% 920K
|
Health Technology
|
| O: 11.11%
H: 19.4%
C: -5.55%
pharmaceuticals network market
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
Published: 2023-12-05 (Crawled : 14:30) - biospace.com/
KTRA | $0.1374 3.54% 3.42% 5.8M
|
Distribution Services
|
| O: 6.58%
H: 0.0%
C: -16.18%
nasdaq granted extension therapeutics
RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration
Published: 2023-11-28 (Crawled : 16:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.04%
H: 0.77%
C: -0.94%
pharmaceuticals collaboration
AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
series care extension therapeutics
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
Published: 2023-10-12 (Crawled : 13:00) - biospace.com/
VRPX | $3.19 0.95% 0.94% 4.7K
|
|
| O: 0.0%
H: 5.13%
C: 5.1%
institute virpax pharmaceuticals research extension
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.45%
H: 0.52%
C: -0.94%
incb5470 positive study
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
Published: 2023-10-04 (Crawled : 13:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K
|
Health Technology
|
| O: 0.87%
H: 2.41%
C: -0.69%
cd45 cell extension grant car-t therapy
OncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer
Published: 2023-10-03 (Crawled : 19:00) - biospace.com/
SLGC | $2.1 -4.76% 34M
|
|
| O: -0.64%
H: 0.0%
C: 0.0%
prophet lung cancer cell trial platform
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Published: 2023-09-27 (Crawled : 14:30) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -0.78%
H: 3.54%
C: 0.0%
HRMY | $29.205 1.23% 1.22% 370K
|
Health Technology
|
| O: 0.82%
H: 1.6%
C: -1.55%
acquire extension
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
Published: 2023-09-22 (Crawled : 13:00) - biospace.com/
ALZN | $0.729 0.47% 0.47% 20K
|
Professional, Scientific, and T...
|
| O: -1.7%
H: 4.4%
C: -2.27%
nasdaq granted extension
ReCode Therapeutics Announces Closing of Extension to Series B Financing
Published: 2023-09-19 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: -1.16%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.09%
H: 1.16%
C: 1.16%
series extension therapeutics
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
disease series extension program therapeutics
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
Published: 2023-08-21 (Crawled : 13:20) - biospace.com/
ANEB | $2.71 -7.14% 8.3K
|
Manufacturing
|
| O: 7.5%
H: 12.62%
C: 2.66%
aneb-001 fda positive extension
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.